A News & Events

Agilent Technologies (A) announced the appointment of Michael Buckner as chief legal officer. Buckner joins Agilent from Danaher Corp. (DHR), where he served as vice president, deputy general counsel, and chief M&A counsel.

Labcorp (LH) announced the nationwide availability of Agilent Technologies' (A) PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. FDA to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's (MRK) Keytruda and Keytruda Qlex the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.